Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Unternehmen & Branche
| Name | 4D Molecular Therapeutics, Inc. |
|---|---|
| Ticker | FDMT |
| CIK | 0001650648 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 485,0 Mio. USD |
| Beta | 2,93 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 85,209,000 | -140,109,000 | -2.42 | 566,711,000 | 505,664,000 |
| 2025-09-30 | 10-Q | 90,000 | -56,876,000 | -1.01 | 423,982,000 | 368,983,000 |
| 2025-06-30 | 10-Q | 15,000 | -54,658,000 | -0.98 | 473,637,000 | 420,890,000 |
| 2025-03-31 | 10-Q | 14,000 | -47,972,000 | -0.86 | 515,729,000 | 469,723,000 |
| 2024-12-31 | 10-K | 37,000 | -160,868,000 | -2.98 | 560,384,000 | 510,606,000 |
| 2024-09-30 | 10-Q | 3,000 | -43,843,000 | -0.79 | 604,028,000 | 552,948,000 |
| 2024-06-30 | 10-Q | 5,000 | -34,953,000 | -0.63 | 620,117,000 | 588,340,000 |
| 2024-03-31 | 10-Q | 28,000 | -32,401,000 | -0.66 | 629,884,000 | 600,561,000 |
| 2023-12-31 | 10-K | 20,723,000 | -100,837,000 | -2.58 | 339,891,000 | 307,829,000 |
| 2023-09-30 | 10-Q | 20,204,000 | -10,256,000 | -0.24 | 361,613,000 | 329,934,000 |
| 2023-06-30 | 10-Q | 239,000 | -29,616,000 | -0.77 | 352,503,000 | 325,144,000 |
| 2023-03-31 | 10-Q | 298,000 | -28,682,000 | -0.88 | 244,021,000 | 218,606,000 |
| 2022-12-31 | 10-K | 3,129,000 | -107,494,000 | -3.32 | 261,846,000 | 231,337,000 |
| 2022-09-30 | 10-Q | 500,000 | -25,691,000 | -0.79 | 280,164,000 | 251,444,000 |
| 2022-06-30 | 10-Q | 162,000 | -28,086,000 | -0.87 | 302,936,000 | 272,517,000 |
| 2022-03-31 | 10-Q | 1,219,000 | -26,338,000 | -0.82 | 324,926,000 | 296,056,000 |
| 2021-12-31 | 10-K | 18,038,000 | -71,317,000 | -2.57 | 353,487,000 | 319,107,000 |
| 2021-09-30 | 10-Q | 1,366,000 | -22,239,000 | -0.82 | 240,618,000 | 224,134,000 |
| 2021-06-30 | 10-Q | 14,580,000 | -7,589,000 | -0.28 | 254,934,000 | 240,646,000 |
| 2021-03-31 | 10-Q | 2,000,000 | -16,406,000 | 270,114,000 | 242,431,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.